Chemomab Therapeutics Ltd.

CMMB Nasdaq SEC CIK 1534248
Follow Chemomab Therapeutics Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 USD · US GAAP
EPS, diluted $0.02 −53.8% vs prior year
Operating cash flow −$11.1M +27.7% vs prior year
Operating income −$112M −8.7% vs prior year

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$11.1M
FY24−$15.4M
FY23−$23.6M
FY22−$20.4M
FY21−$12.6M
FY20−$5.3M
FY19−$16.6M
FY18−$14.4M
FY17-